Size :100ul
Clone Number:
Aliases:DHP antibody; DHPDHase antibody; Dihydropyrimidine dehydrogenase [NADP(+)] antibody; Dihydropyrimidine dehydrogenase [NADP+] antibody; Dihydropyrimidine dehydrogenase antibody; Dihydrothymine dehydrogenase antibody; Dihydrouracil dehydrogenase antibody; DPD antibody; DPYD antibody; DPYD_HUMAN antibody; MGC132008 antibody; MGC70799 antibody; OTTHUMP00000058954 antibody
Product Type:Polyclonal Antibody
Immunogen Species:Homo sapiens (Human)
UniProt ID:Q12882
Immunogen:Recombinant protein of Human DPYD
Raised in:Rabbit
Species Reactivity:Human, Mouse, Rat
Tested Applications:ELISA, WB, IHC; WB:1:500-1:2000, IHC:1:50-1:200
Background:Dihydropyrimidine dehydrogenase (DPD, DPYD) catalyzes the initial and rate-limiting step in uracil and thymidine catabolism as well as catabolism of the chemotherapeutic drug 5-fluorouracil (5-FU) and its derivatives. DPYD deficiency, which results from mutations in the DPYD gene, causes errors in pyrimidine metabolism and potentially life-threatening side effects in cancer patients treated with 5-FU (reviewed in 1). As a result, ongoing work examines whether or how DPYD gene variation and protein expression can be used to predict 5-FU toxicity. Several genes that impart resistance to 5-FU were recently identified in human hepatocellular carcinoma (HCC). AEG-1, which is highly expressed in HCC, increases the expression of DPYD. DPYD is expressed more highly in HCC than in normal liver, and this is thought to be one mechanism of 5-FU resistance.
Clonality:Polyclonal
Isotype:IgG
Purification Method:Affinity purification
Conjugate:Non-conjugated
Buffer:Store at -20°C or -80°C. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form:liquid
Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Target Names:DPYD
Research Areas:Cancer;Metabolism;Signal transduction